Cargando…
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Inhibitors of poly(ADP-ribose) polymerase (PARP)-mediated DNA repair have shown promise in early clinical studies in the treatment of specific subgroups of breast cancer. Notably, phase II trials indicate that olaparib, an oral PARP inhibitor, has activity as a single agent in BRCA-related tumours,...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236327/ https://www.ncbi.nlm.nih.gov/pubmed/21884642 http://dx.doi.org/10.1186/bcr2877 |